Journals / Experimed / 2020 / Cilt: 10 - Sayı: 2

Antibody-depent Immunopathology, Monoclonal Antibodies and Mutations in COVID-19

COVID-19’da Antikor Bağımlı İmmünpataloji, Monoklonal Antikorlar ve Mutasyonlar

Journal
Experimed
Pages
112–118
Publication Date
2020-08-26
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

This review aimed to examine scientific data about ADE, monoclonal antibodies and the possible effects of mutations on the course of the COVID-19 pandemic.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:The Coronavirus disease 19 (COVID-19) pandemic which is the etiological agent of a severe acute respiratory syndrome-associated coronavirus (SARS-CoV-2) has influenced the whole world with the current and possible results.
📊
Key Findings & Data:In order to intervene on COVID-19 and to prevent the SARS-CoV-2 infection, a vaccine design and identification of potential therapeutics and/or targets are a priority.
💡
Conclusion & Impact:This review aimed to examine scientific data about ADE, monoclonal antibodies and the possible effects of mutations on the course of the COVID-19 pandemic.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Koronavirüs · SARS-CoV-2 · COVID-19

Abstract

The Coronavirus disease 19 (COVID-19) pandemic which is the etiological agent of a severe acute respiratory syndrome-associated coronavirus (SARS-CoV-2) has influenced the whole world with the current and possible results. In order to intervene on COVID-19 and to prevent the SARS-CoV-2 infection, a vaccine design and identification of potential therapeutics and/or targets are a priority. The humoral immune responses to viral infections have critical importance for the clearance of pathogens and also to protect from reinfections. However, particularly low affinity antibodies can cause an immune pathology known as antibody-dependent enhancement (ADE). ADE can cause important adversity especially for vaccine designs. Human monoclonal antibody with neutralizing activity is an alternative option in the treatment of the SARS-CoV-2 infection. So, research is ongoing to identify therapeutic monoclonal antibodies in the treatment of the SARS-CoV-2 infection. Identification and understanding of the dynamics of viral mutations is of critical importance to the course and control of the outbreak. Due to the lack of error correction activity of RNA virus polymerases, similar to other RNA viruses of SARS-CoV-2 is expected to have higher mutation rates than DNA viruses. For all the direction and effects of viral mutations occurring during the pandemic are difficult to predict. This review aimed to examine scientific data about ADE, monoclonal antibodies and the possible effects of mutations on the course of the COVID-19 pandemic.

Özet

Şiddetli akut solunum sendromu ilişkili bir koronavirusun (SARSCoV-2) etiyolojik etken olduğu koronavirus 19 hastalığı (COVID-19) pandemisi mevcut ve olası sonuçları ile tüm dünyayı etkisi altına almıştır. COVID-19 ile mücadelede ve SARS-CoV-2 enfeksiyonun önlenmesinde aşı dizaynı ve potansiyel terapötiklerin veya hedeflerin belirlenmesi önceliklidir. Viral enfeksiyonlara karşı oluşan hümoral immun yanıt patojenlerin temizlenmesi ve yeniden bulaşmadan korunmak icin kritik öneme sahiptir. Buna karşın özellikle düşük afiniteli antikorlar, antikor bağımlı alevlenme (ADE) olarak bilinen immün patolojilere neden olabilirler. ADE özellikle aşı tasarımı için önemli sıkıntılara neden olabilir. Nötralizan etkinliğe sahip insan monoklonal antikorları SARS-CoV-2 enfeksiyonunun tedavisinde alternatif bir seçenek oluşturmaktadır. Dolayısıyla SARS-CoV-2 enfeksiyonunun tedavisindeki terapotik monoklonal antikorları tanımlamaya yönelik araştırmalar halen devam etmektedir. Viral mutasyonların tanımlanması ve dinamiğinin anlaşılması salgının seyri ve kontrolü için kritik öneme sahiptir. RNA virüslerinin polimeraz enzimlerinin hata düzeltme aktivitesinin eksik olması nedeniyle SARS-CoV-2’nin de diğer RNA virüslerine benzer olarak mutasyon oranlarının DNA virüslerine göre daha yüksek olması beklenir. Buna karşın pandemi sürecinde meydana gelen viral mutasyonların yönünü ve etkilerini öngörmek zordur. Bu derlemede ADE, monoklonal antikorlar ve mutasyonların COVID-19 pandemisi üzerine olası etkilerine yönelik bilimsel verilerin irdelenmesi amaçlanmıştır.

🔖

Cite This Article

ÇAKAL, B. (2020). Antibody-depent Immunopathology, Monoclonal Antibodies and Mutations in COVID-19. Experimed, Cilt: 10 - Sayı: 2, 112–118. https://ajindex.com/articles/83713

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (1)

  1. Li F. Structure, Function, and Evolution of Coronavirus Spike Proteins. Annu Rev Virol 2016; 29;3(1): 237-26. [CrossRef] 2. Tortorici MA, Veesler D. Structural insights into coronavirus entry. Adv Virus Res 2019; 105: 93-116. [CrossRef] 3. Walls AC, Tortorici MA, Snijder J, Xiong X, Bosch B-J, Rey FA, et al. Tectonic conformational changes of a coronavirus spike glycoprotein promote membrane fusion. Proc Natl Acad Sci USA 2017; 114: 11157-62. [CrossRef] 4. Du L, He Y, Zhou Y, Liu, Zheng B-J, Jiang S. The spike protein of SARS- CoV-a target for vaccine and therapeutic development. Nat Rev Microbiol 2009; 7: 226-36. [CrossRef] 5. Yasui F, Kohara M, Kitabatake M, Nishiwaki T, Fujii H, Tateno C, et al. Phagocytic cells contribute to the antibody- mediated elimination of pulmonary- infected SARS coronavirus. Virology 2014; 454:157-68. [CrossRef] 6. Iwasaki A, Yang Y. The potential danger of suboptimal antibody responses in COVID-19. Nat Rev Immunol. 2020; 20: 339-41. [CrossRef] 7. Zohar T, Alter G. Dissecting antibody-mediated protection against SARS- CoV-2. Nature Review Immunology 2020; 20: 393-5. [CrossRef] 8. Zhao J, Yuan Q, Wang H, Liu W, Liao X, Su Y, Wang X, et al. Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019. Clin Infect Dis 2020; doi: 10.1093/cid/ciaa344. [CrossRef] 9. Peiris JSM, Chu CM, Cheng VCC, Chan KS, Hung IFN, Poon LLM, et al. Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study. Lancet 2003; 361: 1767v72. [CrossRef] 10. Ho M-S, Wei-Ju C, Chen H-Y, Lin S-F, Wang M-C, Di J, et al. Neutralizing antibody response and SARS severity. Emerg Infect Dis 2005; 11: 1730-7. [CrossRef] 11. Robinson WEJr, Montefiori DC, Mitchell WM. Antibody-dependent enhancement of human immunodeficiency virus type 1 infection. Lancet 1988; 8589: 790-4. [CrossRef] 12. Takada A, Feldmann H, Ksiazek TG, Kawaoka Y. Antibody-dependent enhancement of Ebola virus infection. J Virol 2003; 77: 753944. [CrossRef] 13. Wilder-Smith A, Ooi EE, Horstick O, Wills B. Dengue. Lancet 2019; 393: 350-63. [CrossRef] 14. Halstead SB, O'Rourke EJ. Dengue viruses and mononuclear phagocytes. I. Infection enhancement by non-neutralizing antibody. J Exp Med 1977; 146: 201-17. [CrossRef] 15. Sridhar S, Luedtke A, Langevin E, Zhu M, Bonaparte M, Machabert T, et al. Effect of Dengue Serostatus on Dengue Vaccine Safety and Efficacy. N Engl J Med 2018; 379(4): 327-40. [CrossRef] 16. Kliks SC, Nimman